Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totalling 52,600 shares, an increase of 141.3% from the June 30th total of 21,800 shares. Based on an average trading volume of 1,080,000 shares, the short-interest ratio is currently 0.0 days. Approximately 8.1% of the company’s stock are short sold.
Dermata Therapeutics Stock Down 6.2 %
NASDAQ:DRMA traded down $0.16 on Friday, hitting $2.42. The stock had a trading volume of 213,020 shares, compared to its average volume of 533,659. Dermata Therapeutics has a 52 week low of $1.29 and a 52 week high of $23.10. The business’s fifty day moving average is $2.78 and its 200 day moving average is $5.03. The company has a market cap of $1.36 million, a PE ratio of -0.09 and a beta of 0.75.
Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($7.05) earnings per share for the quarter.
Institutional Inflows and Outflows
Dermata Therapeutics Company Profile
Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
Featured Stories
- Five stocks we like better than Dermata Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Which Wall Street Analysts are the Most Accurate?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Stock Analyst Ratings and Canadian Analyst Ratings
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.